CLEANSING COMPOSITIONS WITH MILK PROTEIN AND AROMATHERAPY

Details for Australian Patent Application No. 2003213683 (hide)

Owner PLAYTEX PRODUCTS, INC.

Inventors PITERSKI, Catherine, A.; RICCARDI, Grace

Pub. Number AU-A-2003213683

PCT Number PCT/US03/06450

PCT Pub. Number WO2003/078558

Priority 10/097,057 13.03.02 US

Filing date 4 March 2003

Wipo publication date 29 September 2003

International Classifications

C11D 001/02 Surface-active non-soap detergents -

C11D 003/20 Other compounding ingredients of detergent compositions covered in group - containing oxygen

C11D 003/26 Other compounding ingredients of detergent compositions covered in group - containing nitrogen

C11D 003/50 Other compounding ingredients of detergent compositions covered in group - Perfumes

C11D 001/83 Surface-active non-soap detergents - Mixtures of non-ionic with anionic compounds

C11D 001/94 Surface-active non-soap detergents

Event Publications

31 July 2003 Complete Application Filed

  Priority application(s): 10/097,057 13.03.02 US

6 November 2003 Application Open to Public Inspection

  Published as AU-A-2003213683

2 December 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003213684-Methods of inducing terminal differentiation

2003213682-Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate